Clinical Trial Update: 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk [Phase 2]

View source ↗

Summary

Phase 2 trial assessing five years of adjuvant imatinib in patients with high-risk gastrointestinal stromal tumors; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib (Gleevec) (imatinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: RECRUITING